EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 457 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer August 2, 2021 EMA Recommends Extension of Indications for Pembrolizumab December 14, 2020 Biomarker Data from the KAITLIN Study in High-Risk Early Breast Cancer May 7, 2021 Let’s get to the bottom of it – 7 common cancer... January 4, 2022 Load more HOT NEWS Can Chemotherapy Drugs Be Designed to Avoid Side Effects? Research with Integrity – integrating training into research culture FDA Approves Azacitidine Tablets for Acute Myeloid Leukaemia Breast Cancer Patient Who Continued Teaching Throughout Her Treatment Wins Teacher...
